Dr. Aman Chauhan Presents Phase 1 Study on Neuroendocrine Tumors at ESMO 2025
Earlier from TRON
- ESMO Abstract “1709MO - Multi-center NCI-sponsored phase I study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)”
- Nanopharmaceutics Announces Presentation of National Cancer Institute sponsored Phase I Study with Triapine at ESMO 2025
- Nanopharmaceutics Announces End of Patient Recruitment for NCI Phase II Study with Triapine for Neuroendocrine Tumors
- Nanopharmaceutics Inc. Announces Initiation of Clinical Study of Triapine + Radiation for Glioblastoma or Astrocytoma
- TRON Group Inc. Announces Results of 2025 Annual Meeting of Shareholders
Later from TRON
- Alchem Announces Poster Presentation on its AD=229 Program at Society for Neuroscience 2025 Conference
- AACR 2025 Abstract PS5-07-23
Follow TRON into a list and get an email when it puts out news.
Follow TRON